A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.-Reference-Cited by-同舟云学术

A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5507-5507
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bell-McGuinn Katherine M.¹,Brady William E²,Schilder Russell J.³,Fracasso Paula M⁴,Moore Kathleen N.⁵,Walker Joan L.⁶,Duska Linda R.⁷,Mathews Cara Amanda⁸,Chen Alice⁹,Shepherd Stacie Peacock¹⁰,Giranda Vincent L.¹¹,Aghajanian Carol¹

Affiliation:

1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

2. Roswell Park Cancer Institute, Buffalo, NY

3. Thomas Jefferson University, Philadelphia, PA

4. University of Virginia School of Medicine, Charlottesville, VA

5. University of Oklahoma Health Sciences Center, Oklahoma City, OK

6. Stephenson Cancer Center, OUHSC, Oklahoma City, OK

7. University of Virginia Health System, Charlottesville, VA

8. Women and Infants Hosp of Rhode Island, Providence, RI

9. Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD

10. Abbott, Abbott Park, IL

11. AbbVie, North Chicago, IL